Saskatchewan judge certifies Vioxx class action

A Canadian court has certified a big Vioxx class-action case to include any Canadian patients outside of Quebec; Merck is appealing that decision and vows to fight the entire case, saying that every plaintiff will still have to prove the facts of his or her individual Vioxx side effects. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.